Day: August 8, 2022

Precision BioSciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Read More


- Launched Exclusive In Vivo Gene Insertion Collaboration with Novartis to Develop Single ARCUS Nuclease as Potential One-time Hemoglobinopathy Treatment - Extended Cash Runway to End of 2024 - Reported Updates Across Allogeneic CAR T Pipeline; Interim Results from Lead PBCAR0191 Study with CAR T